| Autor: |
RUDEAN, ANN-KERSTIN M., WERNER, YLVA K., RINGERTZ, OLOF, BYGDEMAN, SOLGUN M., BÄCKMAN, MARIANNE, SANDSTRÖM, ERIC G. |
| Zdroj: |
Sexually Transmitted Diseases; January 1985, Vol. 12 Issue: 1 p19-24, 6p |
| Abstrakt: |
Serogrouping by co-agglutination was used for the characterization of isolates of Neisseria gonorrhoeaein a clinical trial of rosoxacin in Stockholm. Twenty-four isolates (56) belonged to serogroup WI, 17 (40) to WII, and two (5) to WIII. The proportion of WI isolates in Stockholm was reported in earlier studies to be ∼40. On the basis of serogrouping data and clinical information, five (10) of 48 patients in this study were classified as therapeutic failures. Of the initial WI isolates, 22 (92) of 24 were inhibited by 0.03 μg of rosoxacin/ml, as compared with ten (59) of 17 of the intial WII isolates (.05 > P> .01). Thus, this study might under-estimate the failure rate as compared with that for patient populations in which WII isolates are more prevalent, since WI isolates are more susceptible to rosoxacin than WII isolates. A certain WII serovar was correlated with decreased susceptibility to rosoxacin (P< .001). Correlations were found between decreased susceptibility to rosoxacin and decreased susceptibility to other antibiotics (P< .01). A high frequency of side effects (40) was seen among the patients studied. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
